Table 1 Baseline characteristics of female RA patients treated with TNFαI
Characteristic | Value |
|---|---|
All women with RA, n (%) | 45 (100) |
Age (years), mean (SD) | 47.42 (13.70) |
Disease duration (years), median (IQR) | 7 (4–16) |
BMI (kg/m2), mean (SD) | 21.99 (2.26) |
RF positive, n (%) | 44 (97.78) |
Anti-CCP positive, n (%) | 45 (100) |
SJC28, median (IQR) | 8 (5–10) |
TJC28, median (IQR) | 14 (10–19) |
VAS, median (IQR) | 80 (80–80) |
DAS28 ESR, mean (SD) | 6.10 (0.58) |
ESR (mm/h), median (IQR) | 18.0 (11.0–33.0) |
CRP (mg/l), median (IQR) | 5.0 (4.0–14.9) |
TNFαI therapy, n (%) | |
Etanercept (Enbrel) | 19 (42.22) |
Adalimumab (Humira) | 22 (48.89) |
Certolizumab pegol (Cimzia) | 4 (8.89) |